TITLE

Differential Effects of Unfractionated Heparin and Low-Molecular-Weight Heparins on Tissue Thromboplastin Inhibition Test

AUTHOR(S)
Gerbutavicius, Rolandas; Iqbal, Omer; Messmore, Harry; Hoppensteadt, Debra A.; Demir, Muzaffer; Khan, Erum; Bacher, Peter; Fareed, Jawed
PUB. DATE
October 2000
SOURCE
Clinical & Applied Thrombosis/Hemostasis;Oct2000, Vol. 6 Issue 4, p190
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Circulating anticoagulants are endogenously produced substances that interfere with in vitro tests of coagulation like activated partial thromboplastin time (APTT). and cause prolongation of the clotting times. Evaluation of the abnormal APTT involving various factor assays and mixing studies may provide inconclusive and ambiguous results. Tissue thromboplastin inhibition test (TTIT) is one of the screening assays for detection of circulating anticoagulants. However, this test is influenced by the presence of unfractionated heparin (UFH) from concentrations 0.2 U/mL and higher. Since low-molecular-weight heparins (LMWHs) are increasingly used for the prevention of thrombotic disorders and may replace UFH in the future, in this study the authors studied the influence of LMWHs on the performance of TTIT and compared the results with UFH. UFH and LMWHs showed a prolongation of TTIT in the concentration range of 0.25-1.0 U/mL. The marked prolongation of the TTIT with UFH and different LMWHs is in decreasing order of UFH > ardeparin > tinzaparin > dalteparin > enoxaparin. Patients with circulating anticoagulants who are given LMWHs may have false-positive results of TTIT and this influence should be kept in mind during patient management.
ACCESSION #
16793384

 

Related Articles

  • aPTT in Heparinized Patients: Influence of the Interval Between Sampling and Testing. Rachakonda, Vikrant; Rachakonda, Leelanand; Belliveau, Robert R. // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p213 

    Activated partial thromboplastin times(aPTTs) from, 29 whole blood samples were drawn from patients receiving unfractionated heparin through a constant intravenous drip. Three aPTTs were determined for each whole blood sample. The first aPTT was performed on a separate portion of the original...

  • Hemorrhagic Complications in Patients Treated with Anticoagulant Doses of a Low Molecular Weight Heparin (Enoxaparin) in Routine Hospital Practice. Ellis, Martin H.; Hadari, Ruth; Tchuvrero, Noa; Shapira, Shirley; Kovlenko, Irena; Kozmìakova, Mariana; Zissin, Rivka; Elis, Avishay // Clinical & Applied Thrombosis/Hemostasis;Apr2006, Vol. 12 Issue 2, p199 

    Low molecular weight heparins (LMWHs) are a rapidly growing class of anticoagulant drug. Their efficacy has been demonstrated in several clinical settings where they are rapidly becoming the anticoagulant of choice. Controlled clinical studies in patients with deep vein thrombosis, pulmonary...

  • Thrombosis during off pump LVAD placement in a patient with heparin induced thrombocytopenia using bivalirudin. Awad, Hamdy; Bryant, Richard; Malik, Obaid; Dimitrova, Galina; Sai-Sudhakar, Chittoor Bhaskar // Journal of Cardiothoracic Surgery;2013, Vol. 8 Issue 1, p1 

    Here we present our attempt at off pump HeartMate II left ventricular assist device (LVAD) implantation using the anticoagulant bivalirudin in a patient with heparin induced thrombocytopenia, which resulted in thrombosis within the LVAD device. This required that our procedure be converted to on...

  • Taming killer clots. Comarow, Avery // U.S. News & World Report;3/10/2003, Vol. 134 Issue 7, p56 

    Focuses on efforts to treat deep vein thrombosis (DVT) a blood clot that lodges itself in patients' legs. Number of people who have died from DVT; Use of the blood thinner heparin in treating the condition.

  • Initial management of deep venous thrombosis in the outpatient setting. Groce, James B. // American Journal of Health-System Pharmacy;5/1/2008, Vol. 65 Issue 9, p866 

    The article relates the author's perspective concerning the management of deep venous thrombosis (DVT) with low-molecular-weight heparin (LMWH) in an outpatient setting. He contends that outpatient treatment with LMWH is well tolerated and effective and can result in overall cost savings. He...

  • Evaluation of Heparin Assay for Coagulation Management in Newborns Undergoing ECMO. Khaja, Wassia A.; Bilen, Ozlem; Lukner, Ralf B.; Edwards, Rachel; Teruya, Jun // American Journal of Clinical Pathology;Dec2010, Vol. 134 Issue 6, p950 

    The objective was to identify the usefulness of heparin level by anti--factor Xa (anti-Xa) assay vs activated partial thromboplastin time (PTT) or activated clotting time (ACT) in neonates undergoing extracorporeal membrane oxygenation (ECMO). A retrospective record review of 21 patients in the...

  • Usporedba reagensa Pathromtin SL, Dade Actin FS i STA Cephascreen za odreÄ‘ivanje aktiviranog parcijalnog tromboplastinskog vremena. Ðerek, Lovorka; Živković, Marcela; Haćperger, Dragica; Juriček, Jasna; Željko Romić // Biochemia Medica;Apr2008, Vol. 18 Issue 1, p81 

    Aim: Aim of the study was to investigate correlation of activated partial thromboplastin time (APTT) measured with three different reagents: Pathromtin SLand Dade Actin FS reagents on Berichrom Coagulation System analyzer, and by STA Cephascreen reagent on STA Compact analyzer. Material and...

  • Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II. Grouzi, Elisavet // Journal of Blood Medicine;2014, Vol. 5, p131 

    Heparin-induced thrombocytopenia (HIT) is a rare but potentially severe complication of heparin therapy that is strongly associated with venous and arterial thrombosis (HIT and thrombosis syndrome, HITTS), which requires urgent detection and treatment with a nonheparin anticoagulant. Argatroban,...

  • Laboratory Monitoring of Heparin: Challenges and Opportunities. Anne Winkler; Chelsea Sheppard; Corinne Fantz // Laboratory Medicine;Aug2007, Vol. 38 Issue 8, p499 

    Heparin, an anticoagulant used for the treatment and prophylaxis of thrombosis, is most commonly monitored using the activated partial thromboplastin time (APTT). Despite its widespread use, the APTT has limitations which stem from the coagulation factors it measures and the technical...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics